Answers are grounded in this paper and cite their sources.
Purpose of Review This article will review several cases demonstrating breast imaging findings following the use of glucagon-like peptide-1 (GLP-1) agonists, including the relevant implications in changing breast density and supplemental screening. Recent Findings GLP-1 agonists may be associated with breast changes and symptoms that warrant further breast imaging, including supplemental screening and/or for problem solving in the appropriate clinical scenario. Summary Breast imaging findings following the use of GLP-1 agonists may vary, including both significant and insignificant increases in breast density. Patients with increased breast density may warrant further evaluation with supplemental screening. Following the use of GLP-1 agonists, patients may also present with symptoms warranting further targeted imaging evaluation. Knowledge of the spectrum of breast changes associated with GLP-1 agonists is necessary to adequately assess the need for supplemental screening and/or additional targeted breast imaging.
No takes yet. Share an insight, caveat, or question.
Villavicencio et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: